Aprea Therapeutics Q1 EPS $(0.67) Beats $(0.78) Estimate, Sales $380.57K
Portfolio Pulse from Benzinga Newsdesk
Aprea Therapeutics reported Q1 EPS of $(0.67), surpassing the $(0.78) estimate, marking a 50% improvement from last year's $(1.34) per share loss. Sales reached $380.57K.

May 14, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aprea Therapeutics exceeded Q1 EPS estimates and reported a significant year-over-year improvement in losses, alongside modest sales.
Beating EPS estimates and showing a significant reduction in losses compared to the previous year are strong positive signals for investors. The reported sales, although modest, contribute to a positive outlook for the short term. This performance could lead to increased investor confidence and a potential uptick in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100